Franciscus Gasthuis & Vlietland

IceCure's ProSense Cryoablation System Achieves Superior Results in Early-Stage Breast Cancer Trial

- Two peer-reviewed publications from the independent THERMAC trial demonstrate that IceCure's ProSense cryoablation system achieved the highest complete ablation rate compared to alternative thermal ablation techniques with no adverse events. - The study found that 95% of patients were very satisfied or satisfied with thermal ablation treatment, with superior cosmetic outcomes compared to breast-conserving surgery. - Based on the phase II results, investigators concluded that cryoablation is the preferred technique for comparison with surgery in a future phase III trial. - ProSense cryoablation was associated with zero cases requiring oncoplastic surgery, compared to 40% in the radiofrequency ablation group and 11% in the microwave ablation group.